Jesper Brandgaard

Jesper Brandgaard currently works at LEO Pharma A, as Chairman from 2021, Leo Pharma, Inc., as Chairman from 2021, Novo Nordisk Invest 2 A, as Chairman, Novo Nordisk Health Care AG, as Chairman-Supervisory Board, Novo Nordisk Region Japan & Korea A, as Chairman, Novo Nordisk Gsc Holding A, as Chairman, Novo Nordisk Pharmaceuticals A, as Chairman, Novo Nordisk Region China A, as Chairman, Novo Nordisk Region North America Ii A, as Chairman, William Demant Invest A, as Vice Chairman from 2019, Chr.
Hansen A, as Independent Director from 2017, Novo Nordisk Holding Ltd., as Director, Novo Nordisk China Pharmaceuticals Co. Ltd., as Director, William Demant Fonden, as Director from 2019, VækstPartner Kapital ApS, as Director from 2019, and Novo Nordisk Haemophilia Foundation, as Member.
Mr. Brandgaard also formerly worked at SimCorp A, as Chairman from 2008 to 2019, NNIT A, as Chairman from 2002 to 2017, Novo Nordisk Invest 1 A, as Chairman, LEO Pharma NV, as Chairman, Novo Nordisk Region AAMEO & LATAM A, as Chairman, NNE Pharmaplan A, as Chairman, Novo Nordisk Region Europe A, as Chairman, Novonesis A, as Vice Chairman, NNIT A, as Director in 2001, Chr.
Hansen Holding A, as Independent Director from 2017 to 2018, SciClone Pharmaceuticals (Holdings) Ltd., as Non-Executive Director, and Novo Nordisk A, as EVP-Biopharm & Legal Affairs from 2018 to 2019.
Mr. Brandgaard received his graduate degree in 1990 from Copenhagen Business School and Masters Business Admin degree in 1995 from Copenhagen Business School.